Why the study?
Does ANP-receptor antagonism with HS-142-1 alter systemic and renal hemodynamics in rats with heart failure?
Population
Rats with surgically induced myocardial infarction (heart failure model) and sham-operated control rats
Comparison
HS-142-1, a nonpeptide ANP-receptor antagonist vs Sham-operated rats and pre-administration baseline
Design
Preclinical
Key result
Administration of the ANP-receptor antagonist HS-142-1 in heart failure rats significantly reduced plasma cGMP (10.6 vs 2.7 nM, P<0.05) and decreased urine flow and sodium excretion.
Authors
Loading...
Supports ANP-mediated renal compensation in experimental HF; leaves open human translation and therapeutic implications.
Does ANP-receptor antagonism with HS-142-1 alter systemic and renal hemodynamics in rats with heart failure?
Absolute Event Rate: 2.7% vs 10.6%
p-value: p=<0.05
Endogenous ANP in heart failure compensates primarily via diuresis and natriuresis through inhibition of renal tubular reabsorption, rather than by directly maintaining systemic hemodynamics.
Nishikimi et al. (1994) studied Heart failure. HS-142-1 vs. Baseline/Sham-operated rats was evaluated on Plasma concentration of guanosine 3',5'-cyclic monophosphate (p=<0.05). Administration of the ANP-receptor antagonist HS-142-1 in heart failure rats significantly reduced plasma cGMP (10.6 vs 2.7 nM, P<0.05) and decreased urine flow and sodium excretion.